RÉSUMÉ
BACKGROUND AND PURPOSE: Telmisartan suppresses the development of endometriotic lesions. However, the drug also up-regulates the expression of COX-2, which has been suggested to promote the progression of endometriosis. Accordingly, in the present study we analysed whether a combination therapy with telmisartan and a COX-2 inhibitor may be more effective in the treatment of endometriotic lesions than the application of telmisartan alone. EXPERIMENTAL APPROACH: Endometriotic lesions were induced in the peritoneal cavity of C57BL/6 mice, which were treated daily with an i.p. injection of telmisartan (10 mg·kg-1 ), parecoxib (5 mg·kg-1 ), a combination of telmisartan and parecoxib or vehicle. Therapeutic effects on lesion survival, growth, vascularization, innervation and protein expression were studied over 4 weeks by high-resolution ultrasound imaging as well as immunohistochemical and Western blot analyses. KEY RESULTS: Telmisartan-treated lesions exhibited a significantly reduced lesion volume when compared with vehicle-treated controls and parecoxib-treated lesions. This inhibitory effect of telmisartan was even more pronounced when it was used in combination with parecoxib. The combination therapy resulted in a reduced microvessel density as well as lower numbers of proliferating Ki67-positive cells and higher numbers of apoptotic cleaved caspase-3-positive stromal cells within the lesions. This was associated with a lower expression of COX-2, MMP-9 and p-Akt/Akt when compared with controls. The application of the two drugs further inhibited the ingrowth of nerve fibres into the lesions. CONCLUSIONS AND IMPLICATIONS: Combination therapy with telmisartan and a COX-2 inhibitor represents a novel, effective pharmacological strategy for the treatment of endometriosis.
Sujet(s)
Antagonistes du récepteur de type 1 de l'angiotensine-II/usage thérapeutique , Benzimidazoles/usage thérapeutique , Benzoates/usage thérapeutique , Inhibiteurs de la cyclooxygénase 2/usage thérapeutique , Endométriose/traitement médicamenteux , Isoxazoles/usage thérapeutique , Animaux , Caspase-3/métabolisme , Cyclooxygenase 2/métabolisme , Modèles animaux de maladie humaine , Association de médicaments , Endométriose/imagerie diagnostique , Endométriose/métabolisme , Endométriose/anatomopathologie , Femelle , Matrix metalloproteinase 9/métabolisme , Souris de lignée C57BL , Récepteur PPAR gamma/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Telmisartan , ÉchographieRÉSUMÉ
The incorporation of endothelial progenitor cells (EPCs) into microvessels contributes to the vascularization of endometriotic lesions. Herein, we analyzed whether this vasculogenic process is regulated by estrogen. Estrogen- and vehicle-treated human EPCs were analyzed for migration and tube formation. Endometriotic lesions were induced in irradiated FVB/N mice, which were reconstituted with bone marrow from FVB/N-TgN (Tie2/green fluorescent protein) 287 Sato mice. The animals were treated with 100 µg/kg ß-estradiol 17-valerate or vehicle (control) over 7 and 28 days. Lesion growth, cyst formation, homing of green fluorescent protein(+)/Tie2(+) EPCs, vascularization, cell proliferation, and apoptosis were analyzed by high-resolution ultrasonography, caliper measurements, histology, and immunohistochemistry. Numbers of blood circulating EPCs were assessed by flow cytometry. In vitro, estrogen-treated EPCs exhibited a higher migratory and tube-forming capacity when compared with controls. In vivo, numbers of circulating EPCs were not affected by estrogen. However, estrogen significantly increased the number of EPCs incorporated into the lesions' microvasculature, resulting in an improved early vascularization. Estrogen further stimulated the growth of lesions, which exhibited massively dilated glands with a flattened layer of stroma. This was mainly because of an increased glandular secretory activity, whereas cell proliferation and apoptosis were not markedly affected. These findings indicate that vasculogenesis in endometriotic lesions is dependent on estrogen, which adds a novel hormonally regulated mechanism to the complex pathophysiology of endometriosis.
Sujet(s)
Endométriose/anatomopathologie , Progéniteurs endothéliaux/anatomopathologie , Oestradiol/analogues et dérivés , Néovascularisation pathologique/métabolisme , Animaux , Mouvement cellulaire/effets des médicaments et des substances chimiques , Mouvement cellulaire/physiologie , Modèles animaux de maladie humaine , Progéniteurs endothéliaux/effets des médicaments et des substances chimiques , Oestradiol/métabolisme , Oestradiol/pharmacologie , Oestrogènes/métabolisme , Oestrogènes/pharmacologie , Femelle , Cytométrie en flux , Humains , Immunohistochimie , Souris , Souris transgéniques , Néovascularisation pathologique/anatomopathologie , Réaction de polymérisation en chaîne , TranscriptomeRÉSUMÉ
Tubeimoside-1 (TBMS1) is a potent anti-tumor phytochemical. Its functional and molecular mode of action, however, remains elusive so far. Since angiogenesis is essential for tumor progression and metastasis, we herein investigated the anti-angiogenic effects of the compound. In a non-small cell lung cancer (NSCLC) xenograft model we found that treatment of CD1 nu/nu mice with TBMS1 (5 mg/kg) significantly suppressed the growth and vascularization of NCI-H460 flank tumors. Moreover, TBMS1 dose-dependently reduced vascular sprouting in a rat aortic ring assay. In vitro, TBMS1 induced endothelial cell apoptosis without decreasing the viability of NSCLC tumor cells and inhibited the migration of endothelial cells by disturbing their actin filament organization. TBMS1 further stimulated the proteasomal degradation of vascular endothelial growth factor receptor-2 (VEGFR2) and Tie2 in endothelial cells, which down-regulated AKT/mTOR signaling. These findings indicate that TBMS1 represents a novel phytochemical for anti-angiogenic treatment of cancer and other angiogenesis-related diseases.
Sujet(s)
Tumeurs du poumon/traitement médicamenteux , Récepteur TIE-2/métabolisme , Saponines/usage thérapeutique , Triterpènes/usage thérapeutique , Récepteur-2 au facteur croissance endothéliale vasculaire/métabolisme , Animaux , Modèles animaux de maladie humaine , Humains , Tumeurs du poumon/anatomopathologie , Souris , Néovascularisation pathologique , Rats , Récepteur TIE-2/génétique , Saponines/administration et posologie , Transduction du signal , Triterpènes/administration et posologie , Récepteur-2 au facteur croissance endothéliale vasculaire/génétique , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
Catalase and ABCD3 are frequently used as markers for the localization of peroxisomes in morphological experiments. Their abundance, however, is highly dependent on metabolic demands, reducing the validity of analyses of peroxisomal abundance and distribution based solely on these proteins. We therefore attempted to find a protein which can be used as an optimal marker for peroxisomes in a variety of species, tissues, cell types and also experimental designs, independently of peroxisomal metabolism. We found that the biogenesis protein peroxin 14 (PEX14) is present in comparable amounts in the membranes of every peroxisome and is optimally suited for immunoblotting, immunohistochemistry, immunofluorescence, and immunoelectron microscopy. Using antibodies against PEX14, we could visualize peroxisomes with almost undetectable catalase content in various mammalian tissue sections (submandibular and adrenal gland, kidney, testis, ovary, brain, and pancreas from mouse, cat, baboon, and human) and cell cultures (primary cells and cell lines). Peroxisome labeling with catalase often showed a similar tissue distribution to the mitochondrial enzyme mitochondrial superoxide dismutase (both responsible for the degradation of reactive oxygen species), whereas ABCD3 exhibited a distinct labeling only in cells involved in lipid metabolism. We increased the sensitivity of our methods by using QuantumDots™, which have higher emission yields compared to classic fluorochromes and are unsusceptible to photobleaching, thereby allowing more exact quantification without artificial mistakes due to heterogeneity of individual peroxisomes. We conclude that PEX14 is indeed the best marker for labeling of peroxisomes in a variety of tissues and cell types in a consistent fashion for comparative morphometry.
Sujet(s)
Protéines membranaires/analyse , Péroxysomes/composition chimique , Péroxysomes/métabolisme , Protéines de répression/analyse , Glandes surrénales/composition chimique , Glandes surrénales/cytologie , Animaux , Marqueurs biologiques/analyse , Encéphale/cytologie , Chats , Cellules cultivées , Femelle , Humains , Rein/composition chimique , Rein/cytologie , Mâle , Souris , Ovaire/composition chimique , Ovaire/cytologie , Pancréas/composition chimique , Pancréas/cytologie , Papio , Rats , Testicule/composition chimique , Testicule/cytologieRÉSUMÉ
Cre-mediated excision of loxP sites is widely used in mice to manipulate gene function in a tissue-specific manner. To analyze phenotypic alterations related to Cre-expression, we have used AMH-Cre-transgenic mice as a model system. Different Cre expression levels were obtained by investigation of C57BL/6J wild type as well as heterozygous and homozygous AMH-Cre-mice. Our results indicate that Cre-expression itself in Sertoli cells already has led to oxidative stress and lipid peroxidation (4-HNE lysine adducts), inducing PPARα/γ, peroxisome proliferation and alterations of peroxisome biogenesis (PEX5, PEX13 and PEX14) as well as metabolic proteins (ABCD1, ABCD3, MFP1, thiolase B, catalase). In addition to the strong catalase increase, a NRF2- and FOXO3-mediated antioxidative response (HMOX1 of the endoplasmic reticulum and mitochondrial SOD2) and a NF-κB activation were noted. TGFß1 and proinflammatory cytokines like IL1, IL6 and TNFα were upregulated and stress-related signaling pathways were induced. Sertoli cell mRNA-microarray analysis revealed an increase of TNFR2-signaling components. 53BP1 recruitment and expression levels for DNA repair genes as well as for p53 were elevated and the ones for related sirtuin deacetylases affected (SIRT 1, 3-7) in Sertoli cells. Under chronic Cre-mediated DNA damage conditions a strong downregulation of Sirt1 was observed, suggesting that the decrease of this important coordinator between DNA repair and metabolic signaling might induce the repression release of major transcription factors regulating metabolic and cytokine-mediated stress pathways. Indeed, caspase-3 was activated and increased germ cell apoptosis was observed, suggesting paracrine effects. In conclusion, the observed wide stress-induced effects and metabolic alterations suggest that it is essential to use the correct control animals (Cre/Wt) with matched Cre expression levels to differentiate between Cre-mediated and specific gene-knock out-mediated effects.
Sujet(s)
Antioxydants/métabolisme , Integrases/métabolisme , Péroxysomes/métabolisme , Transduction du signal/physiologie , Sirtuines/métabolisme , Animaux , Hormone antimullérienne/génétique , Cellules cultivées , Marche sur chromosome , Génotype , Integrases/génétique , Mâle , Souris , Souris de lignée C57BL , Souris transgéniques , Réaction de polymérisation en chaîne , Régions promotrices (génétique)/génétique , Réaction de polymérisation en chaine en temps réel , Cellules de Sertoli/métabolisme , Transduction du signal/génétique , Sirtuines/génétique , Testicule/métabolismeRÉSUMÉ
Peroxisomes are organelles with main functions in the metabolism of lipids and of reactive oxygen species. Within the testis, they have different functional profiles depending on the cell types. A dysfunction of peroxisomes interferes with regular spermatogenesis and can lead to infertility due to spermatogenic arrest. However, so far only very little is known about the functions of peroxisomes in germ cells. We have therefore analyzed the peroxisomal compartment in germ cells and its alterations during spermatogenesis by fluorescence and electron microscopy as well as by expression profiling of peroxisome-related genes in purified cell populations isolated from mouse testis. We could show that peroxisomes are present in all germ cells of the germinal epithelium. During late spermiogenesis, the peroxisomes form large clusters that are segregated from the spermatozoa into the residual bodies upon release from the germinal epithelium. Germ cells express genes for proteins involved in numerous metabolic pathways of peroxisomes. Based on the expression profile, we conclude that newly identified functions of germ cell peroxisomes are the synthesis of plasmalogens as well as the metabolism of retinoids, polyunsaturated fatty acids and polyamines. Thus, germ cell peroxisomes are involved in the regulation of the homeostasis of signaling molecules regulating spermatogenesis and they contribute to the protection of germ cells against oxidative stress.
Sujet(s)
Cellules germinales/métabolisme , Stress oxydatif , Péroxysomes/génétique , Spermatogenèse , Testicule/cytologie , Animaux , Différenciation cellulaire , Analyse de profil d'expression de gènes , Cellules germinales/cytologie , Mâle , Souris , Souris de lignée C57BL , Souris transgéniques , Microscopie électronique , Microscopie de fluorescence , Microscopie immunoélectronique , Stress oxydatif/génétique , Péroxysomes/métabolisme , RT-PCR , Spermatogenèse/génétique , Testicule/métabolismeRÉSUMÉ
The vital importance of peroxisomal metabolism for regular function of the testis is stressed by the severe spermatogenesis defects induced by peroxisomal dysfunction. However, only sparse information is available on the role and enzyme composition of this organelle in distinct cell types of the testis. In the present study, we characterized the peroxisomal compartment in human and mouse testis in primary cultures of murine somatic cells (Sertoli, peritubular myoid, and Leydig cells) and in GFP-PTS1 transgenic mice with a variety of morphological and biochemical techniques. Formerly, peroxisomes were thought to be absent in late stages of spermatogenesis. However, our results obtained by detection of different peroxisomal marker proteins show the presence of these organelles in most cell types in the testis, except for mature spermatozoa. Furthermore, we demonstrate a strong heterogeneity of peroxisomal protein content in various cell types of the human and mouse testis and show marked differences in structure, abundance, and localization of these organelles in spermatids, depending on their maturation. Highest and selective enrichment of the peroxisomal lipid transporters (ABCD1 and ABCD3) as well as ACOX2, the key regulatory enzyme of the beta-oxidation pathway 2 for side chain oxidation of cholesterol, were found in Sertoli cells, whereas Leydig cells were enriched in catalase and ABCD2. Our results suggest a cell type-specific metabolic function of peroxisomes in the testis and point to an important role for peroxisomes in spermiogenesis and in the lipid metabolism of Sertoli cells.